Medical Therapy. Efficacy or Lack of Efficacy

Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease

Michael G. Katz, Dan G. Ohad, Philip Putter, Nataly Shtraizent, Ehud Shahar, Smadar Tal, Efrat EliyahuIcahn School of Medicine at Mount Sinai. Veterinary Teaching Hospital of the Koret School of Veterinary Medicine and Hebrew University of Jerusalem. Spot On Veterinary Hospital. Senex. Frezent Biological Solutions. Tel-Hai College. Migal-Galilee Research Institute. United States and Israel Frontiers in Veterinary MedicineFront Vet Med 2024; 11: DOI: 10.3389/fvets.2024.1415030 AbstractMyxomatous

Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease Read More »

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure

Xiaofeng Wang, Shilin Wang, Ruihuan Shen, Zhongyuan Lu, Xu WangFuwai Hospital, Beijing Hospital and Chinese Academy of Medical Sciences and Peking Union Medical College.China European Journal of Medical ResearchEur J Med Res 2024; 29: DOI: 10.1186/s40001-024-02077-y AbstractObjective: Total cavo-pulmonary connection (TCPC) is a palliative treatment for single ventricular malformations. For high-risk patients (preoperative mean pulmonary arterial pressure,

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure Read More »

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Marius M. Hoeper, David B. Badesch, H. Ardeschir Ghofrani, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Valerie V. McLaughlin, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Ekkehard Grünig, Grzegorz Kopeć, Gisela Meyer, Karen M. Olsson, Stephan Rosenkranz, Yayun Xu, Barry Miller, Marcie Fowler, John Butler, Jeorg Koglin, Janethe de Oliveira Pena, and Marc Humbert, for

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension Read More »

Patterns and Outcomes of Epoprostenol Use in Infants with Congenital Diaphragmatic Hernia Requiring Extracorporeal Life Support

Nikhil R. Shah, Keerthi Burgi, Dimitra M. Lotakis, Mary K. Olive, Amanda D. McCormick, Erin E. Perrone, Joseph T. Church, George B. MychaliskaC.S. Mott Children’s Hospital, Michigan Medicine and University of Michigan Medical School. United States Journal of PediatricsJ Pediatr 2024; DOI: 10.1016/j.jpeds.2024.114286 AbstractObjective: To describe our experience utilizing epoprostenol for pulmonary hypertension (PH) in infants with

Patterns and Outcomes of Epoprostenol Use in Infants with Congenital Diaphragmatic Hernia Requiring Extracorporeal Life Support Read More »

Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors

Herlina Dimiati Dimas Arya Umara, Iflan NaufalUniversitas Syiah Kuala,Indonesia F1000 ResearchF1000Res 2022; DOI: 10.12688/f1000research.53966.2 AbstractRespiratory tract infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first occurred in Wuhan, China, in December 2019 and was declared as a pandemic by WHO. The interaction between the 2019 coronavirus disease (COVID-19) and pulmonary hypertension (PH) in children

Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors Read More »

Embracing the challenges of neonatal and paediatric pulmonary hypertension

Dunbar Ivy, Erika B. Rosenzweig, Steven H. Abman, Maurice Beghetti, Damien Bonnet, Johannes Menno Douwes, Alessandra Manes, RolfM.F.BergerUniversity of Colorado School of Medicine and Children’s Hospital Colorado. Maria Fareri Children’s Hospital at WMC Health and New York Medical College of Touro University. Geneva University Hospital and University of Geneva. Necker Hospital for Sick Children. Beatrix

Embracing the challenges of neonatal and paediatric pulmonary hypertension Read More »

Intravenous magnesium sulfate in pulmonary hypertension of the newborn: a systematic review

G. Cuttone, C. Minardi, G. Baronti, C. Zanza, Y. Longhitano, L. La ViaASP Trapani.Italy European Review for Medical and Pharmacological SciencesEur Rev Med Pharmacol Sci 2024; DOI: 10.26355/eurrev_202408_36637 AbstractObjective: Pulmonary hypertension in the newborn (PPHN) is a significant clinical condition characterized by elevated pulmonary artery pressures, leading to serious health consequences. Magnesium sulfate, known for its vasodilatory

Intravenous magnesium sulfate in pulmonary hypertension of the newborn: a systematic review Read More »

Atypical presentation and management of a neonate with alveolar capillary dysplasia: A case report

Niki Dermitzaki, Nikitas Chatzigiannis, Maria Baltogianni, Maria E. Kamperi, Antonios Vlahos, Alexandros Makis, Konstantinos Douros, Vasileios GiaprosUniversity of Ioannina. Athens University Medical School and “Attikon” University Hospital.Greese Pediatric PulmonologyPediatr Pulmonol 2024; DOI: 10.1002/ppul.27241 AbstractAbstract Not Available CategoryClass III. Pulmonary Hypertension Associated with Developmental Diseases of the LungMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric

Atypical presentation and management of a neonate with alveolar capillary dysplasia: A case report Read More »

A Single Center Experience of Pulmonary Arterial Hypertension Management in Korea: A 25-Year Comparative Analysis Following the Introduction of Targeted Therapy

Ji Hyun Cha I-Seok Kang, Shin Yi Jang, June Huh Jeong Hoon Yang, Jinyoung Song, Taek Kyu Park, Seung Woo Park, Hojoong Kim, Duk-Kyung Kim Sung-A ChangSamsung Medical Center, Samsung Changwon Hospital and Sungkyunkwan University School of Medicine. Republic of Korea Korean Circulation JournalKorean Circ J 2024; DOI: 10.4070/kcj.2023.0316 AbstractBackground and objectives: The transformation of pulmonary arterial

A Single Center Experience of Pulmonary Arterial Hypertension Management in Korea: A 25-Year Comparative Analysis Following the Introduction of Targeted Therapy Read More »

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression

Ekaterina Legchenko, Philippe Chouvarine, Fatimunnisa Qadri, Edgar Specker, Marc Nazaré, Radoslaw Wesolowski, Susann Matthes, Michael Bader, Georg HansmannHannover Medical School. Max-Delbrück-Center for Molecular Medicine. Trypto Therapeutics GmbH. German Center for Cardiovascular Research. Charité Universitätsmedizin Berlin. University of Lübeck. Friedrich-Alexander-University Erlangen-Nürnberg. Germany Journal of the Amerian College of Cardiology Basic to Translational ScienceJACC Basi Transl Sci

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression Read More »

Scroll to Top